

In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma

NCT05636540

Status	RECRUITING
Phase	Early Phase 1
Sponsor	Heather Wachtel
Enrollment	30 participants

Key Eligibility Criteria

Inclusion (4)

- Participants will be e 18 years of age.
- Clinical diagnosis of pheochromocytoma or paraganglioma based on biochemical and imaging studies At least one lesion identified on standard of care imaging (e.g. CT, MRI, FDG or 68-Gallium dotatate, other PET/CT or MIBG).
- Standard of care germline genetic testing performed for clinical purposes or participant's consent for germline genetic testing for research purposes.
- Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.

Exclusion (3)

- Inability to tolerate imaging procedures in the opinion of an investigator or treating physician.
- Females who are pregnant or breastfeeding will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential prior to FTT injection.
- Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study.

Locations (1 total)

Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States